Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 705 · Innovation in Pediatric Drugs Act of 2025 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 355c Research into pediatric uses for drugs and biological products

+18 −87 of 9 shown
More for 21 U.S.C. § 355c
Read § 355cOnly this section
9 changes the bill asks for here, 7 carried out
  1. Carried out:

    in paragraph (1), by striking Beginning 270 and inserting Noncompliance letter.—Beginning 270;

  2. Carried out:

    by striking The drug or and inserting Effect of noncompliance.—The drug or; and

  3. Not carried out:

    by striking (except that the drug or biological product shall not be subject to action under section 303) and inserting (except that the drug or biological product shall be subject to action under section 303 only if such person demonstrated a lack of due diligence in satisfying the applicable requirement); and

    “(except that the drug or biological product shall not be subject to action under section 303)” isn't in § 355c(d)(2) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“(except that the drug or biological product shall not be subject to action under section 303)” not found in /us/usc/t21/s355c/d/2
  4. Carried out:

    by adding at the end the following:(3) Limitation.— The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed..

    The section already has a provision under this letter or number, so it would have two.

  5. Not carried out:

    Section 505B(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(d)), as amended by subsection (a), is further amended by adding at the end the following:(4) Due diligence.— Before the Secretary may conclude that a person failed to submit or otherwise meet a requirement as described in the matter preceding paragraph (1), the Secretary shall— (A) issue a noncompliance letter pursuant to paragraph (1); (B) provide such person with …

    The law already reads this way: § 355c(d)(4) is already as the bill would have it.

    Technical detailalready there: /us/usc/t21/s355c/d/4 reads as the bill would have it
  6. Carried out:

    Section 505B(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(k)) is amended to read as follows:(k) Relation to orphan drugs.— (1) In general.— This section does not apply to a drug or biological product for an indication for which orphan designation has been granted under section 526 unless the Secretary determines that pediatric assessments of such drug or biological …

  7. Carried out:

    in subsection (a)(5), by adding at the end the following:(E) Automatic full waiver list.— The Secretary shall maintain a list, posted on the website of the Food and Drug Administration, of adult-related diseases and conditions— (i) with respect to which the necessary studies are impossible or highly impracticable, as described in …

  8. Carried out:

    in subsection (b)(2), by adding at the end the following:(E) Automatic full waiver list.— The Secretary shall maintain a list, posted on the website of the Food and Drug Administration, of adult-related diseases and conditions with respect to which the necessary studies would meet the criteria for a full waiver under subparagraph (A).; and

  9. Carried out:

    in subsection (e)(4), by adding at the end the following: If, at the time of an applicant’s submission of the initial pediatric study plan, the disease or condition for which the drug is intended to treat appears on the list under subsection (a)(5)(E), then the assessments for such disease or condition shall be waived under subsection (a)(5)..

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

1 of the 9 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.

§ 355c(a)–(b)

Start of § 355c to (a)(5)(B)(iv) unchanged ·

(C) Pediatric formulation not possible If a partial waiver is granted on the ground that it is not possible to develop a pediatric formulation, the waiver shall cover only the pediatric groups requiring that formulation. An applicant seeking such a partial waiver shall submit to the Secretary documentation detailing why a pediatric formulation cannot be developed and, if the waiver is granted, the applicant’s submission shall promptly be made available to the public in an easily accessible manner, including through posting on the Web site of the Food and Drug Administration.

(D) Labeling requirement If the Secretary grants a full or partial waiver because there is evidence that a drug or biological product would be ineffective or unsafe in pediatric populations, the information shall be included in the labeling for the drug or biological product.

(E) [inserted: Automatic full waiver list.—] [inserted: The Secretary shall maintain a list, posted on the website of the Food and Drug Administration, of adult-related diseases and conditions—]

(i) [inserted: with respect to which the necessary studies are impossible or highly impracticable, as described in subparagraph (A)(i); or]

(ii) [inserted: for which a drug or biological product for such disease or condition otherwise meets the criteria described in subparagraph (A).]

(b) Marketed drugs and biological products

(1) In general The Secretary may (by order in the form of a letter) require the sponsor or holder of an approved application for a drug under section 355 of this title or the holder of a license for a biological product under section 262 of title 42 to submit by a specified date the assessments described in subsection (a)(2), if the Secretary finds that—

§ 355c(b)–(c)

(b)(1)(A)–(2)(B) unchanged ·

(C) Pediatric formulation not possible If a waiver is granted on the ground that it is not possible to develop a pediatric formulation, the waiver shall cover only the pediatric groups requiring that formulation. An applicant seeking either a full or partial waiver shall submit to the Secretary documentation detailing why a pediatric formulation cannot be developed and, if the waiver is granted, the applicant’s submission shall promptly be made available to the public in an easily accessible manner, including through posting on the Web site of the Food and Drug Administration.

(D) Labeling requirement If the Secretary grants a full or partial waiver because there is evidence that a drug or biological product would be ineffective or unsafe in pediatric populations, the information shall be included in the labeling for the drug or biological product.

(E) [inserted: Automatic full waiver list.—] [inserted: The Secretary shall maintain a list, posted on the website of the Food and Drug Administration, of adult-related diseases and conditions with respect to which the necessary studies would meet the criteria for a full waiver under subparagraph (A).]

(3) Effect of subsection Nothing in this subsection alters or amends section 331(j) of this title or section 552 of title 5 or section 1905 of title 18.

(c) Meaningful therapeutic benefit For the purposes of paragraph (4)(A)(iii)(I) and (4)(B)(iii)(I) of subsection (a) and paragraphs (1)(B) and (2)(B)(iii)(I)(aa) of subsection (b), a drug or biological product shall be considered to represent a meaningful therapeutic benefit over existing therapies if the Secretary determines that—

§ 355c(d)Submission of assessments and reports on the investigation(1)–(2)

(c)(1)–(2) unchanged ·

(d) Submission of assessments and reports on the investigation If a person fails to submit a required assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), fails to meet the applicable requirements in subsection (a)(4), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply:

(1) Noncompliance letter [inserted: Noncompliance letter.—]Beginning 270 days after July 9, 2012, the Secretary shall issue a non-compliance letter to such person informing them of such failure to submit or meet the requirements of the applicable subsection. Such letter shall require the person to respond in writing within 45 calendar days of issuance of such letter. Such response may include the person’s request for a deferral extension if applicable. Such letter and the person’s written response to such letter shall be made publicly available on the Internet Web site of the Food and Drug Administration 60 calendar days after issuance, with redactions for any trade secrets and confidential commercial information. If the Secretary determines that the letter was issued in error, the requirements of this paragraph shall not apply. The Secretary shall inform the Pediatric Advisory Committee of letters issued under this paragraph and responses to such letters.

(2) Effect of noncompliance [inserted: Effect of noncompliance.—]The drug or biological product that is the subject of an assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), applicable requirements in subsection (a)(4), or request for approval of a pediatric formulation, may be considered misbranded solely because of that failure and subject to relevant enforcement action (except that the drug or biological product shall be subject to action under section 333 of this title only if such person demonstrated a lack of due diligence in satisfying the applicable requirement), but such failure shall not be the basis for a proceeding—

(A) to withdraw approval for a drug under section 355(e) of this title; or

(B) to revoke the license for a biological product under section 262 of title 42.

§ 355c(d)–(e)

(d)(3)–(4) unchanged ·

(B) provide such person with a 45-day period beginning on the date of receipt of such noncompliance letter to respond in writing as set forth in such paragraph; and

(C) after reviewing such written response, determine whether the person demonstrated a lack of due diligence in satisfying such requirement.

(3) [inserted: Limitation.—] [inserted: The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed.]

(e) Pediatric study plans

(1) In general An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2) or the investigation described in subsection (a)(3). The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).1

§ 355c(e)Pediatric study plans(3)–(6)

(e)(2) unchanged ·

(3) Agreed initial pediatric study plan Not later than 90 calendar days following the meeting under paragraph (2)(C)(i)(II) or the receipt of a written response from the Secretary under paragraph (2)(C)(iii), the applicant shall document agreement on the initial pediatric study plan in a submission to the Secretary marked “Agreed Initial Pediatric Study Plan”, and the Secretary shall confirm such agreement to the applicant in writing not later than 30 calendar days of receipt of such agreed initial pediatric study plan.

(4) Deferral and waiver If the agreed initial pediatric study plan contains a request from the applicant for a deferral, partial waiver, or waiver under this section, the written confirmation under paragraph (3) shall include a recommendation from the Secretary as to whether such request meets the standards under paragraphs (3) or (4) of subsection (a).[inserted: If, at the time of an applicant’s submission of the initial pediatric study plan, the disease or condition for which the drug is intended to treat appears on the list under subsection (a)(5)(E), then the assessments for such disease or condition shall be waived under subsection (a)(5).]

(5) Amendments to the agreed initial pediatric study plan At the initiative of the Secretary or the applicant, the agreed initial pediatric study plan may be amended at any time. The requirements of paragraph (2)(C) shall apply to any such proposed amendment in the same manner and to the same extent as such requirements apply to an initial pediatric study plan under paragraph (1). The requirements of paragraphs (3) and (4) shall apply to any agreement resulting from such proposed amendment in the same manner and to the same extent as such requirements apply to an agreed initial pediatric study plan.

(6) Internal committee The Secretary shall consult the internal committee under section 355d of this title on the review of the initial pediatric study plan, agreed initial pediatric study plan, and any significant amendments to such plans.

§ 355c(i)–(l)

(e)(7)–(i)(3) unchanged ·

(4) Effect The requirements of this subsection shall supplement, not supplant, other review of such adverse event reports by the Secretary.

(j) Scope of authority Nothing in this section provides to the Secretary any authority to require a pediatric assessment of any drug or biological product, or any assessment regarding other populations or uses of a drug or biological product, other than the pediatric assessments described in this section.

(k) Relation to orphan drugs[inserted: .—]

(1) In general[struck: ; exemption for orphan indications][inserted: .—] [struck: Unless][inserted: This] [struck: the Secretary requires otherwise by regulation and except as provided in paragraph (2), this ]section does not apply to [struck: any][inserted: a] drug or biological product for an indication for which orphan designation has been granted under section [struck: 360bb][inserted: 526] [inserted: unless the Secretary determines that pediatric assessments ]of [inserted: such drug or biological product required under ]this [struck: title][inserted: section could represent a meaningful therapeutic benefit as described in subsection (c)].

(2) [struck: Applicability][inserted: Deferrals] [struck: despite][inserted: and] [struck: orphan designation of certain indications][inserted: waivers.—] [struck: This][inserted: Deferrals] [struck: section][inserted: and] [inserted: waivers under subsections (a)(4) and (a)(5) ]shall apply [struck: with][inserted: to] [struck: respect][inserted: assessments] [struck: to][inserted: described] [struck: a][inserted: in] [struck: drug][inserted: this] [struck: or][inserted: subsection] [struck: biological][inserted: to] [struck: product][inserted: the] [struck: for][inserted: same] [struck: which][inserted: extent] [struck: an][inserted: and] [struck: indication][inserted: in] [struck: has][inserted: the] [struck: been][inserted: same] [struck: granted][inserted: manner] [struck: orphan][inserted: as] [struck: designation][inserted: such] [struck: under][inserted: deferrals] [struck: 360bb][inserted: and] [struck: of][inserted: waivers] [struck: this][inserted: apply] [struck: title][inserted: with] [struck: if][inserted: respect] [inserted: to ]the [struck: investigation][inserted: assessments] [struck: described][inserted: under] [struck: in ]subsection (a)([struck: 3][inserted: 1])[inserted: ,] [struck: applies][inserted: and] [inserted: waivers under subsection (b)(2) shall apply ]to [inserted: assessments described in this subsection to ]the [struck: drug][inserted: same] [struck: or][inserted: extent] [struck: biological][inserted: and] [struck: product][inserted: in] [inserted: the same manner ]as [struck: described][inserted: such] [struck: in][inserted: waivers] [inserted: apply with respect to the assessments required pursuant to ]subsection ([struck: a][inserted: b])(1)[struck: (B)].

(l) New active ingredient

(1) Non-interchangeable biosimilar biological product A biological product that is biosimilar to a reference product under section 262 of title 42, and that the Secretary has not determined to meet the standards described in subsection (k)(4) of such section for interchangeability with the reference product, shall be considered to have a new active ingredient under this section.

Rest of § 355c unchanged ·

21 U.S.C. § 355c–1 Report

+3 −12 of 4 shown
More for 21 U.S.C. § 355c–1
Read § 355c–1Only this section
4 changes the bill asks for here, 2 carried out
  1. Carried out:

    in paragraph (11), by striking the semicolon at the end and inserting , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions;;

  2. Not carried out:

    in paragraph (15), by striking and at the end;

    The bill strikes “and” at the end of § 355c–1(b)(15), but the text there doesn't end with it. The law may have changed since the bill was drafted.

    Technical detail“and” is not at the end of /us/usc/t21/s355c–1/b/15
  3. Not carried out:

    in paragraph (16), by striking the period at the end and inserting ; and; and

    The bill strikes “.” at the end of § 355c–1(b)(16), but the text there doesn't end with it. The law may have changed since the bill was drafted.

    Technical detail“.” is not at the end of /us/usc/t21/s355c–1/b/16
  4. Carried out:

    by adding at the end the following:(17) a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the …

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 355c–1(b)Contents(10)–(12)

Start of § 355c–1 to (b)(9) unchanged ·

(10) an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 355a and 355c of this title;

(11) an assessment of the impact of the amendments to such section 355c of this title made by the FDA Reauthorization Act of 2017 on pediatric research and labeling of drugs and biological products and pediatric labeling of molecularly targeted drugs and biological products for the treatment of cancer, including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions[inserted: , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions];

(12) an assessment of the efforts of the Secretary to implement the plan developed under section 505C–1 of the Federal Food, Drug, and Cosmetic Act,1 regarding earlier submission of pediatric studies under sections 355a and 355c of this title and section 262(m) of title 42, including—

(A) the average length of time after the approval of an application under section 355(b)(1) of this title or section 262(a) of title 42 before studies conducted pursuant to such section 355a of this title, 355c of this title, or section 262(m) of title 42 are completed, submitted, and incorporated into labeling;

§ 355c–1(b)–(c)

(b)(12)(B)–(15) unchanged ·

(16) the Secretary’s assessment of the overall impact of the amendments made by section 504 of the FDA Reauthorization Act of 2017 on the conduct and effectiveness of pediatric cancer research and the orphan drug program, as well any subsequent recommendations; and

(17) a listing of penalties, settlements, or payments under section 333 of this title for failure to comply with requirements under such section 355c of this title, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed.

(17) [inserted: a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed.]

(c) Stakeholder comment At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.

42 U.S.C. § 284m Program for pediatric studies of drugs

+2 −5Shown
More for 42 U.S.C. § 284m
Read § 284mOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 409I(d) of the Public Health Service Act (42 U.S.C. 284m(d)) is amended to read as follows:(d) Funding.— Of the amount made available for pediatric research to each national research institute and national center under this title for each of fiscal years 2026 through 2030, the Director of NIH is authorized to make available up to one percent of such amount for pediatric research under this section..

§ 284m(c)–(d)

Start of § 284m to (c)(9) unchanged ·

(10) Failure to agree If a holder of an approved application for a drug, within 30 days after receiving a request to make a labeling change under paragraph (9), does not agree to make a requested labeling change, the Commissioner of Food and Drugs may deem the drug to be misbranded under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.].

(11) No effect on authority Nothing in this subsection limits the authority of the United States to bring an enforcement action under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] when a drug lacks appropriate pediatric labeling. Neither course of action (the Pediatric Advisory Committee process or an enforcement action referred to in the preceding sentence) shall preclude, delay, or serve as the basis to stay the other course of action.

(d) [struck: Authorization of appropriations][inserted: Funding.—] [inserted: Of the amount made available for pediatric research to each national research institute and national center under this title for each of fiscal years 2026 through 2030, the Director of NIH is authorized to make available up to one percent of such amount for pediatric research under this section.]

[struck: (1)] [struck: In general] [struck: There are authorized to be appropriated to carry out this section, $25,000,000 for each of fiscal years 2026 through 2028.]

[struck: (2)] [struck: Availability] [struck: Any amount appropriated under paragraph (1) shall remain available to carry out this section until expended.]

21 U.S.C. § 333 Penalties

Couldn't place the change
More for 21 U.S.C. § 333
Read § 333Only this section

The bill's words for this section

  1. Not carried out:

    Section 303(f)(4)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333(f)(4)(A)) is amended by striking or 505–1 and inserting 505–1, or 505B.

    “or 505–1” isn't in § 333(f)(4)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“or 505–1” not found in /us/usc/t21/s333/f/4/A

Step through the changes